PTC Therapeutics' gene therapy is already approved in the European ... while European stocks rose on hopes of a better growth ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Wall Street analysts opine that Bicycle Therapeutics plc (NASDAQ:BCYC)’s expansion beyond oncology will diversify its ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning, and welcome to the Axsome Therapeutics Third ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

With consumer spending comprising 68% of the U.S. economy, analysts emphasized that a robust job market remains central to ...

Axsome Therapeutics surpassed revenue expectations in Q3, driven by strong sales from its key products.

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer price index ...

Joseph Schwartz, an analyst from Leerink Partners, reiterated the Hold rating on PTC Therapeutics (PTCT – Research Report). The ...